Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population

BACKGROUND AND OBJECTIVE: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) were used to treat non-small cell lung cancer (NSCLC) patients with EGFR mutation positive. This study aims to compare the effectiveness of first line TKIs; gefitinib, erlotinib, and afatinib in the treatment of advanced stage NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: SUTANDYO, Noorwati, HANAFI, Arif, JAYUSMAN, Mulawarman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754576/
https://www.ncbi.nlm.nih.gov/pubmed/31526459
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754576/
https://www.ncbi.nlm.nih.gov/pubmed/31526459
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.02

Ejemplares similares